New Delhi: In a significant step towards bolstering India’s clinical research capabilities, the Indian Council of Medical Research (ICMR) has signed Memorandum of Agreement (MoAs) with key industry players to conduct First-in-Human Phase-1 Clinical Trials for four promising therapeutic candidates under its Phase 1 Clinical Trial Network.
As part of these strategic collaborations, ICMR will work with Aurigene Oncology Limited on a small molecule for multiple myeloma, partner with Indian Immunologicals Limited for Zika vaccine development, coordinate a seasonal influenza vaccine trial with Mynvax Private Limited, and explore CAR-T cell therapy advancements for chronic lymphocytic leukemia with ImmunoACT.
Union Health Minister J P Nadda lauded the partnerships, calling them a pivotal step toward “affordable and accessible cutting-edge treatments” that solidify India’s standing as a global healthcare innovation leader.
”Establishing Phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions,” said Dr Rajiv Bahl, Secretary, Department of Health Research & Director General, ICMR, added.
The clinical trials will take place at four premier institutions: KEMH & GSMC in Mumbai, ACTREC in Navi Mumbai, SRM MCH&RC in Kattankulathur, and PGIMER in Chandigarh. A Central Coordinating Unit at ICMR Headquarters, New Delhi, will oversee the operations, ensuring the trials’ smooth execution through dedicated infrastructure and manpower at each site.
